5.2 Systemic Medications and Drug Interactions in Dentistry

2.2 Systemic Medications and Drug Interactions in Dentistry

INBDE Core Concept: Managing dental patients taking systemic medications requires precise knowledge of prophylactic antibiotic guidelines, bleeding control for antithrombotic therapy, antiresorptive-induced osteonecrosis risks, blood pressure action cutoffs, glycemic management, and immunosuppression management.

---

Antibiotic Prophylaxis Guidelines (2021 AHA Revisions)

The American Heart Association (AHA) and American Dental Association (ADA) restrict infective endocarditis (IE) antibiotic prophylaxis exclusively to patient groups at the highest risk of adverse outcomes from endocarditis.

Cardiac Indications for Prophylaxis

Prophylaxis is recommended ONLY for invasive dental procedures involving manipulation of gingival tissue, the periapical region of teeth, or perforation of the oral mucosa in patients with:

1. Prosthetic cardiac valves or prosthetic material used for cardiac valve repair (including transcatheter valves).
2. Previous history of Infective Endocarditis (IE).
3. Uncorrected cyanotic congenital heart disease (CHD), including palliative shunts and conduits.
4. Completely repaired CHD with prosthetic material or device during the first 6 months after the procedure.
5. Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or device.
6. Cardiac transplant recipients who develop cardiac valvulopathy.

INBDE Trap: Antibiotic prophylaxis is NOT recommended for mitral valve prolapse, rheumatic heart disease, bicuspid aortic valve, coronary artery stents, or prosthetic joint replacements (per ADA guidelines, routine prophylaxis for joint replacements is not supported by evidence).

Prophylactic Regimens (Administered 30–60 Minutes Prior to Procedure)

CRITICAL GUIDELINE UPDATE: Clindamycin is NO LONGER recommended by the AHA for infective endocarditis prophylaxis due to its disproportionate risk of causing severe, potentially fatal Clostridioides difficile colitis.

---

Anticoagulants and Antiplatelet Therapy

Dental surgical management requires balancing the risk of intraoperative hemorrhage against the risk of thromboembolic stroke or vascular occlusion.

Hemostasis Spectrum:
Thromboembolic Risk (Stopping Drug) ◄───────────────► Hemorrhage Risk (Continuing Drug)
                    Target Range for Minor Surgery: Stable INR < 3.5

Warfarin (Coumadin)

• Mechanism: Vitamin K antagonist that inhibits hepatic synthesis of Vitamin K-dependent clotting factors (II, VII, IX, X).
• Monitoring: Evaluated using the Prothrombin Time (PT) and International Normalized Ratio (INR).
• Surgical Rule: For minor oral surgical procedures (simple extractions, single implants, periodontal scaling), Warfarin should NOT be discontinued if the patient's INR is stable and < 3.5. Local hemostatic agents (tranexamic acid mouthwash, oxidized cellulose, gelfoam, surgical sutures) effectively control local bleeding.

Direct Oral Anticoagulants (DOACs)

DOACs act directly on specific steps of the coagulation cascade and have largely replaced warfarin in clinical medicine.

Surgical Management: DOACs do not alter INR. For minor oral procedures, morning doses may be held or delayed until after surgery, but routine cessation is rarely indicated without consulting the prescribing physician.

Antiplatelet Medications

• Aspirin: Irreversibly inhibits COX-1, blocking thromboxane $A_2$ ($TXA_2$) synthesis for the 7–10 day lifespan of the platelet.
• Clopidogrel (Plavix): Irreversibly blocks the $P2Y_{12}$ adenosine diphosphate (ADP) receptor on platelets.
• Surgical Management: Neither aspirin nor clopidogrel should be stopped prior to dental extractions. Discontinuation drastically increases the risk of arterial thrombosis.

---

Antiresorptives, Bisphosphonates, and MRONJ

Medication-Related Osteonecrosis of the Jaw (MRONJ) is a severe adverse effect associated with antiresorptive and antiangiogenic therapies that inhibit bone remodeling and angiogenesis.

Antiresorptive Drug Classes & Mechanisms

• Bisphosphonates (IV: Zoledronic acid, Pamidronate; Oral: Alendronate, Risedronate, Ibandronate): Incorporate into hydroxyapatite crystals, taken up by osteoclasts during bone resorption, and inhibit farnesyl pyrophosphate synthase (FPPS), inducing osteoclast apoptosis.
• RANKL Inhibitors (Denosumab / Prolia / Xgeva): Monoclonal antibody that binds to receptor activator of nuclear factor-$\kappa$B ligand (RANKL), preventing osteoclast maturation and activation. Unlike bisphosphonates, denosumab does not bind bone matrix; its antiresorptive effect wanes ~6 months after cessation.
• Antiangiogenic Agents (Bevacizumab, Sunitinib): Inhibit vascular endothelial growth factor (VEGF) signaling, impairing new vessel formation and bone vascularity.

Diagnostic Criteria for MRONJ (AAOMS Guidelines)

A clinical diagnosis of MRONJ requires ALL three of the following criteria:

1. Current or previous treatment with antiresorptive or antiangiogenic agents.
2. Exposed bone or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region that has persisted for more than 8 weeks.
3. No history of radiation therapy to the jaws or obvious metastatic disease to the jaws.

MRONJ Clinical Staging & Management Strategies

Dental Clinical Rules: Complete all invasive dental extractions and periodontal therapy BEFORE initiating IV bisphosphonate therapy for oncology. For patients already on oral bisphosphonates (>4 years or with risk factors), consider a 2-month drug holiday prior to elective oral surgery if cleared by the prescribing physician.

---

Antihypertensive Medications & Dental Management Cutoffs

High blood pressure is extremely prevalent in dental populations. Antihypertensive medications interact with vasoconstrictors and dental analgesics.

Major Antihypertensive Classes & Dental Implications

• ACE Inhibitors (Lisinopril, Enalapril): Block conversion of Angiotensin I to Angiotensin II. Side effects include a persistent dry cough (due to bradykinin accumulation) and potential angioedema.
• Angiotensin Receptor Blockers (ARBs - Losartan, Valsartan): Block $AT_1$ receptors directly without causing bradykinin accumulation (no dry cough).
• Beta-Blockers:
  • Cardioselective ($\beta_1$): Metoprolol, Atenolol. Safe with standard dental local anesthetic vasoconstrictors.
  • Non-Selective ($\beta_1 + \beta_2$): Propranolol, Nadolol. CRITICAL DRUG INTERACTION: Exogenous epinephrine acts on unblocked vascular $\alpha_1$ receptors while $\beta_2$ vasodilation is blocked by propranolol, causing severe hypertensive crisis followed by vagal reflex bradycardia. Limit epinephrine to 0.04 mg (maximum 2 cartridges of 1:100,000 epi).
• Calcium Channel Blockers (CCBs - Nifedipine, Amlodipine, Diltiazem): Inhibit L-type calcium channels in vascular smooth muscle and myocardium. Nifedipine frequently causes gingival overgrowth / hyperplasia starting in the interdental papillae.
• Diuretics (Hydrochlorothiazide, Furosemide): Can cause orthostatic (postural) hypotension; advise patients to transition slowly from supine to upright dental chair positions. NSAIDs taken for >5 days attenuate the antihypertensive efficacy of diuretics and ACE inhibitors by inhibiting renal prostaglandins.

ASA Physical Status & Blood Pressure Cutoffs (2017 ACC/AHA Guidelines)

---

Antidiabetic Medications & Glycemic Protocols

Uncontrolled diabetes impairs neutrophil function, wound healing, and collagen synthesis, significantly exacerbating periodontal disease and surgical complication rates.

Diagnostic Thresholds & Glycemic Control

• HbA1c Target: Normal < 5.7%; Well-controlled diabetic < 7.0%; Uncontrolled diabetic > 8.0% (increased surgical infection risk).
• Fasting Plasma Glucose (FPG): Target 80–130 mg/dL. Values > 200 mg/dL warrant deferral of elective surgical procedures.

Antidiabetic Pharmacotherapy

• Insulin (Rapid-, Short-, Intermediate-, Long-acting): Replaces endogenous insulin in Type 1 DM and advanced Type 2 DM. Highest risk for acute hypoglycemia.
• Biguanides (Metformin): First-line oral agent for Type 2 DM. Decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity. Does NOT cause hypoglycemia when used as monotherapy.
• Sulfonylureas (Glipizide, Glyburide, Glimepiride): Stimulate pancreatic $\beta$-cells to secrete insulin. High risk of hypoglycemia if meal intake is skipped.
• Incretin Therapies (GLP-1 Receptor Agonists - Semaglutide; DPP-4 Inhibitors - Sitagliptin): Enhance glucose-dependent insulin secretion.

Dental Management & Acute Hypoglycemia Protocol

• Appointment Scheduling: Treat diabetic patients in the morning after they have taken their normal antidiabetic dose and eaten a normal breakfast (endogenous cortisol levels are highest in the morning, mitigating hypoglycemia risk).
• Conscious Hypoglycemic Patient ("Rule of 15"):
  • Symptoms: Tremors, diaphoresis, tachycardia, confusion, dizziness.
  • Action: Administer 15–20 grams of fast-acting oral carbohydrates (e.g., 4 oz orange juice, 3–4 glucose tablets). Wait 15 minutes and recheck blood glucose. Repeat if blood glucose remains < 70 mg/dL.
• Unconscious Hypoglycemic Patient:
  • Action: Call EMS (911) immediately. Maintain airway. Administer 1 mg Glucagon IM/SC or 50 mL of 50% Dextrose (D50W) IV.

---

Immunosuppressive Therapies, Adrenal Insufficiency, and Cytopenias

Patients undergoing organ transplantation, autoimmune disease management (e.g., rheumatoid arthritis, lupus), or cancer chemotherapy take systemic immunosuppressants.

Key Immunosuppressive Agents

• Corticosteroids (Prednisone, Dexamethasone): Potent anti-inflammatory agents that suppress phospholipase $A_2$ and leukocyte migration. Chronic use causes secondary adrenal insufficiency.
• Calcineurin Inhibitors (Cyclosporine, Tacrolimus): Block T-cell activation by inhibiting calcineurin-mediated IL-2 transcription. Cyclosporine causes gingival overgrowth / hyperplasia in ~30% of patients (combining cyclosporine with nifedipine markedly exacerbates gingival enlargement).
• Biologic Response Modifiers (TNF-$\alpha$ Inhibitors - Infliximab, Adalimumab): Increase susceptibility to opportunistic fungal and mycobacterial infections.

Exogenous Steroids & Adrenal Crisis ("Rule of 2s")

Exogenous steroid administration suppresses the hypothalamic-pituitary-adrenal (HPA) axis.

$\text{Adrenal Suppression Risk Factors:} \quad \ge 20\text{ mg prednisone/day} \quad \text{for } \ge 2\text{ consecutive weeks} \quad \text{within the past } 2\text{ years}$

• Adrenal Crisis Manifestations: Severe hypotension, hypovolemic shock, confusion, vomiting, abdominal pain.
• Current Supplementation Guidelines: Routine non-surgical dental procedures and minor extractions under local anesthesia DO NOT require routine steroid stress coverage. Patients should take their normal daily morning dose. For major surgical stress (extensive multi-hour maxillofacial trauma or reconstructive surgery), consult the physician to consider doubling the daily dose on the day of surgery.

Hematologic Cytopenias & Absolute Neutrophil Count (ANC)